Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Nobelpharma Co., Ltd.

https://www.nobelpharma.co.jp/en/

Latest From Nobelpharma Co., Ltd.

Pipeline Watch: Phase III Starts With Murepavadin, CSL112 And Vibegron

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Pipeline Watch Approvals

Japan Grants Global First Nod For Brodalumab, For Psoriasis

Japan has granted the first approval worldwide for brodalumab as a biologic therapy for psoriasis, one of two new antibodies for the disorder in a new batch of approvals that also includes Praluent and Kyprolis.

BioPharmaceutical Asia Pacific

Endometriosis: 176 Million Women And No Cure In Sight

With a gap in endometriosis treatments on the market, Citeline analyst Benjamin Graham looks at the pipeline to see what those suffering can expect in the coming years.

Therapy Areas Gynecology & Urology

Japan listing sets stage for edoxaban, vaniprevir launches

Japan has granted reimbursement prices to a batch of new drugs, including a new therapy for hepatitis C, a novel anticoagulant and a new insomnia treatment.

Cardiovascular Infectious Diseases
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Other Names / Subsidiaries
    • Nobelpharma America LLC
UsernamePublicRestriction

Register